



Substitute form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	88870.007
-------	---	----	---	------------------------	-----------

Complete if Known

Application Number	10/598,700
Filing Date	
First Named Inventor	RAY, Partho S., et al.
Group Art Unit	
Examiner Name	

FOREIGN PATENT DOCUMENTS

Exam. Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant	Publication Date (MM-YYYY)	Trans.
		Office	Number	Kind Code (if known)			
		WO	2003/087138	A2	Rigel Pharmaceuticals, Inc.	10-2003	
		WO	1994/005813	A1	Mochida Pharmaceutical Co.	03-1994	

NON-PATENT LITERATURE DOCUMENTS

Exam. Initials	Cite No.	Include: Name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Trans.
		IMBERT, I., et al., "Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins" <i>Journal of General Virology</i> , 2003, Vol. 84, pp. 1549-1557.	
		TALLET-LOPEZ, B., et al. "Antisense oligonucleotides targeted to the domain IIIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation" <i>Nucleic Acids Research</i> , 2003, Vol. 31, No. 2, pp. 734-742.	

Examiner Signature	/Sean McGarry/	Date Considered	05/07/2008
--------------------	----------------	-----------------	------------